|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing Kif2a induces apoptosis in squamous cell carcinoma of the oral tongue through inhibition of the PI3K/Akt signaling pathway.
|
24248467 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Computational analysis indicated that miR-296-3p targeted PTEN, which regulates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and PTEN is involved in the carcinogenesis of SCC. miR-296-3p directly regulated PTEN expression in head and neck cancer cells, with PTEN protein levels decreased in 4/19 the SCCs (21.0%), as compared with those in the IPs (76.4%).
|
28693263 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An increase in the copy number of PIK3CA, although small, was detected in 57.1% (8/14) of OSCC lines and 16.7% (18/108) of OSCC tumors using quantitative real-time PCR.
|
17052259 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
PIK3CA mutation incidence was significantly lower in adenocarcinoma (2/135, 1.5%) than in squamous cell carcinoma (5/77, 6.5%, p=0.0495).
|
16930767 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting the PI3K-AKT-mTOR and/or cyclin pathway components in SCC may be warranted.
|
26030731 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
|
23607916 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erratum: Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells.
|
30867805 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells.
|
29616118 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
|
11959846 |
2002 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA copy number gains were more frequent in squamous cell carcinoma (33.1%) than in adenocarcinoma (6.2%) or SCLC lines (4.7%).
|
18757405 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations and amplification are detected in 1% of primary lung adenocarcinomas (ADCs) and in 38% of primary lung squamous cell carcinomas.
|
27007084 |
2016 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Head and neck squamous cell carcinomas exhibit variable sensitivity to inhibitors of the PI3K/mTOR pathway, an important target of genomic alterations in this cancer type.
|
25977343 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway.
|
31638186 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In tumor types with more than 10 patients tested, PIK3CA mutations were most frequent in endometrial (3 of 14, 21%), ovarian (5 of 30, 17%), colorectal (9 of 54, 17%), breast (2 of 14, 14%), cervical (2 of 15, 13%), and squamous cell cancer of the head and neck (1 of 11, 9%).
|
21216929 |
2011 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA amplification incidence was significantly higher in male, smoker and squamous cell carcinoma patients.
|
17681398 |
2007 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, blocking the whole PI3K-AKT-mTOR pathway with the PI3K/mTOR dual inhibitor BEZ235 also showed efficacy in treating this subtype of lung SqCC.
|
26216950 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Whether they function as direct precursors to a less common form of squamous cell carcinoma will require further study, but carcinomas associated with these lesions might warrant testing for PIK3CA mutations to address this question.
|
27834349 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations were preferentially detected in patients with adenocarcinomas, and the frequency of PIK3CA mutations in patients with squamous cell carcinomas was higher than that in patients with other histological cancer types.
|
31757465 |
2020 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>PAR-2</i> promotes cell proliferation, migration, and invasion through activating PI3K/AKT signaling pathway in oral squamous cell carcinoma.
|
31213575 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
|
17549376 |
2007 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of 675 tumors revealed activation of PIK3CA and other PI3K/AKT pathway genes in 31% of squamous carcinomas and 24% of adeno- and adenosquamous tumors, predominantly at two sites (E542K, E545K) in the helical domain of the PIK3CA gene.
|
26080840 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We therefore analyzed 102 large-cell carcinomas by immunohistochemistry for TTF-1 and ΔNp63/p40 as classifiers for adenocarcinoma and squamous cell carcinoma, respectively, and correlated the resulting subtypes with nine therapeutically relevant genetic alterations characteristic of adenocarcinoma (EGFR, KRAS, BRAF, MAP2K1/MEK1, NRAS, ERBB2/HER2 mutations and ALK rearrangements) or more common in squamous cell carcinoma (PIK3CA and AKT1 mutations).
|
23196793 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After SCC transformation, the absence of G45 domain in DeltaG45 cells was associated with deficient extracellular signal-regulated kinase and phosphotidylinositol 3-kinase (PI3K) pathway activation, impaired invasion, deficient metalloproteinase activity, and absent tumorgenicity in vivo.
|
18413757 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
|
12375266 |
2002 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The majority of OSCC cell lines showed an activation of PI3K/Akt signaling, and enforced expression of NDRG2 in HSC-3 cells decreased the level of phosphorylated Akt at Serine 473 (p-Akt).
|
20045673 |
2010 |